ASRT

Assertio Holdings operates as a specialty pharmaceutical company marketing branded prescription medicines treating pain, inflammation, and central nervous system disorders through commercial partnerships and proprietary sales efforts. Headquartered in Lake Forest, Illinois, Assertio's commercial portfolio includes INDOCIN oral suspension for treating moderate to severe rheumatoid arthritis, osteoarthritis, and gout; CAMBIA powder for oral solution addressing acute migraine treatment; ZIPSOR liquid-filled capsules for mild to moderate acute pain; SPRIX nasal spray for short-term pain management; and ROLVEDON for reducing chemotherapy-induced neutropenia. The company acquires or licenses mature branded products from larger pharmaceutical manufacturers seeking to divest non-core assets, then maximizes product value through focused commercial strategies targeting specialist prescribers including rheumatologists, pain management physicians, and oncologists. Assertio's business model emphasizes commercial execution with relatively modest research and development spending compared to traditional pharmaceutical companies, instead investing in targeted sales forces, medical education programs, and patient access initiatives supporting branded product utilization. The company reported annual revenues of approximately $125-150 million with operating leverage improving as commercial infrastructure spreads across expanding product portfolios. Assertio faces generic competition pressures as product patents expire, reimbursement challenges with payers questioning branded product value versus generic alternatives, and regulatory scrutiny of opioid-related products including SPRIX nasal spray which contains ketorolac raising DEA and FDA compliance considerations. Recent strategic priorities include pursuing additional product acquisitions, expanding international distribution partnerships, and developing specialty pharmacy distribution channels enhancing patient access and medication adherence.